273 related articles for article (PubMed ID: 15993078)
1. Synthesis and antitumor evaluation of novel 5-substituted-4-hydroxy-8-nitroquinazolines as EGFR signaling-targeted inhibitors.
Jin Y; Li HY; Lin LP; Tan J; Ding J; Luo X; Long YQ
Bioorg Med Chem; 2005 Oct; 13(19):5613-22. PubMed ID: 15993078
[TBL] [Abstract][Full Text] [Related]
2. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.
Rusnak DW; Affleck K; Cockerill SG; Stubberfield C; Harris R; Page M; Smith KJ; Guntrip SB; Carter MC; Shaw RJ; Jowett A; Stables J; Topley P; Wood ER; Brignola PS; Kadwell SH; Reep BR; Mullin RJ; Alligood KJ; Keith BR; Crosby RM; Murray DM; Knight WB; Gilmer TM; Lackey K
Cancer Res; 2001 Oct; 61(19):7196-203. PubMed ID: 11585755
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of substituted 6-alkynyl-4-anilinoquinazoline derivatives as potent EGFR inhibitors.
Liu LT; Yuan TT; Liu HH; Chen SF; Wu YT
Bioorg Med Chem Lett; 2007 Nov; 17(22):6373-7. PubMed ID: 17889528
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases.
Xu G; Searle LL; Hughes TV; Beck AK; Connolly PJ; Abad MC; Neeper MP; Struble GT; Springer BA; Emanuel SL; Gruninger RH; Pandey N; Adams M; Moreno-Mazza S; Fuentes-Pesquera AR; Middleton SA; Greenberger LM
Bioorg Med Chem Lett; 2008 Jun; 18(12):3495-9. PubMed ID: 18508264
[TBL] [Abstract][Full Text] [Related]
5. Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors.
Rheault TR; Caferro TR; Dickerson SH; Donaldson KH; Gaul MD; Goetz AS; Mullin RJ; McDonald OB; Petrov KG; Rusnak DW; Shewchuk LM; Spehar GM; Truesdale AT; Vanderwall DE; Wood ER; Uehling DE
Bioorg Med Chem Lett; 2009 Feb; 19(3):817-20. PubMed ID: 19111461
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, antitumor evaluations and molecular modeling studies of novel 3,5-substituted indolin-2-one derivatives.
Li HH; Zheng XH; Tan JZ; Chen LL; Liu H; Luo XM; Shen X; Lin LP; Chen KX; Ding J; Jiang HL
Acta Pharmacol Sin; 2007 Jan; 28(1):140-52. PubMed ID: 17184594
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.
Suzuki T; Fujii A; Ohya J; Nakamura H; Fujita F; Koike M; Fujita M
Cancer Sci; 2009 Aug; 100(8):1526-31. PubMed ID: 19459856
[TBL] [Abstract][Full Text] [Related]
8. Discovering novel 3-nitroquinolines as a new class of anticancer agents.
Li HH; Huang H; Zhang XH; Luo XM; Lin LP; Jiang HL; Ding J; Chen KX; Liu H
Acta Pharmacol Sin; 2008 Dec; 29(12):1529-38. PubMed ID: 19026174
[TBL] [Abstract][Full Text] [Related]
9. Alkynyl pyrimidines as dual EGFR/ErbB2 kinase inhibitors.
Waterson AG; Stevens KL; Reno MJ; Zhang YM; Boros EE; Bouvier F; Rastagar A; Uehling DE; Dickerson SH; Reep B; McDonald OB; Wood ER; Rusnak DW; Alligood KJ; Rudolph SK
Bioorg Med Chem Lett; 2006 May; 16(9):2419-22. PubMed ID: 16483772
[TBL] [Abstract][Full Text] [Related]
10. 4'-Alkoxyl substitution enhancing the anti-mitotic effect of 5-(3',4',5'-substituted)anilino-4-hydroxy-8-nitroquinazolines as a novel class of anti-microtubule agents.
Jin Y; Zhou ZY; Tian W; Yu Q; Long YQ
Bioorg Med Chem Lett; 2006 Nov; 16(22):5864-9. PubMed ID: 16942876
[TBL] [Abstract][Full Text] [Related]
11. Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series.
Petrov KG; Zhang YM; Carter M; Cockerill GS; Dickerson S; Gauthier CA; Guo Y; Mook RA; Rusnak DW; Walker AL; Wood ER; Lackey KE
Bioorg Med Chem Lett; 2006 Sep; 16(17):4686-91. PubMed ID: 16777410
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of thiazolidinone derivatives as potential EGFR and HER-2 kinase inhibitors.
Lv PC; Zhou CF; Chen J; Liu PG; Wang KR; Mao WJ; Li HQ; Yang Y; Xiong J; Zhu HL
Bioorg Med Chem; 2010 Jan; 18(1):314-9. PubMed ID: 19914835
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and in vitro antitumor activity of 4-aminoquinoline and 4-aminoquinazoline derivatives targeting EGFR tyrosine kinase.
Abouzid K; Shouman S
Bioorg Med Chem; 2008 Aug; 16(16):7543-51. PubMed ID: 18678492
[TBL] [Abstract][Full Text] [Related]
14. Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.
Tsou HR; Overbeek-Klumpers EG; Hallett WA; Reich MF; Floyd MB; Johnson BD; Michalak RS; Nilakantan R; Discafani C; Golas J; Rabindran SK; Shen R; Shi X; Wang YF; Upeslacis J; Wissner A
J Med Chem; 2005 Feb; 48(4):1107-31. PubMed ID: 15715478
[TBL] [Abstract][Full Text] [Related]
15. Novel C-5 aminomethyl pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases.
Mastalerz H; Chang M; Gavai A; Johnson W; Langley D; Lee FY; Marathe P; Mathur A; Oppenheimer S; Tarrant J; Tokarski JS; Vite GD; Vyas DM; Wong H; Wong TW; Zhang H; Zhang G
Bioorg Med Chem Lett; 2007 May; 17(10):2828-33. PubMed ID: 17368025
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines.
Ban HS; Tanaka Y; Nabeyama W; Hatori M; Nakamura H
Bioorg Med Chem; 2010 Jan; 18(2):870-9. PubMed ID: 19969465
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of epidermal growth factor receptor-mediated signaling by "Combi-triazene" BJ2000, a new probe for Combi-Targeting postulates.
Brahimi F; Matheson SL; Dudouit F; McNamee JP; Tari AM; Jean-Claude BJ
J Pharmacol Exp Ther; 2002 Oct; 303(1):238-46. PubMed ID: 12235257
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, biological evaluation and molecular docking studies of amide-coupled benzoic nitrogen mustard derivatives as potential antitumor agents.
Zheng QZ; Zhang F; Cheng K; Yang Y; Chen Y; Qian Y; Zhang HJ; Li HQ; Zhou CF; An SQ; Jiao QC; Zhu HL
Bioorg Med Chem; 2010 Jan; 18(2):880-6. PubMed ID: 20005116
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and structure-activity relationships of N-benzyl-N-(X-2-hydroxybenzyl)-N'-phenylureas and thioureas as antitumor agents.
Li HQ; Yan T; Yang Y; Shi L; Zhou CF; Zhu HL
Bioorg Med Chem; 2010 Jan; 18(1):305-13. PubMed ID: 19914837
[TBL] [Abstract][Full Text] [Related]
20. New dual inhibitors of EGFR and HER2 protein tyrosine kinases.
Fink BE; Vite GD; Mastalerz H; Kadow JF; Kim SH; Leavitt KJ; Du K; Crews D; Mitt T; Wong TW; Hunt JT; Vyas DM; Tokarski JS
Bioorg Med Chem Lett; 2005 Nov; 15(21):4774-9. PubMed ID: 16111887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
